MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted immunotherapies for cancer. Founded in 2018 and headquartered in Chicago, Illinois, the company's mission is to develop potential first-in-class drugs with novel mechanisms of action designed to significantly improve and extend the lives of cancer patients.

The company's lead product candidate is ateganosine (THIO), also known as 6-thio-dG or 6-thio-2'-deoxyguanosine. THIO is an investigational telomere-targeting agent currently in clinical development, primarily focusing on telomerase-positive cancer cells, with a significant emphasis on Non-Small Cell Lung Cancer (NSCLC). The therapeutic approach involves administering THIO, which disrupts telomere structure and function, followed by immune checkpoint inhibitors such as cemiplimab (Libtayo) or atezolizumab (Tecentriq), to enhance anti-tumor immune responses. MAIA Biotechnology is also advancing a pipeline of second-generation telomere targeting agents, including THIO-102 and THIO-103, and exploring other hard-to-treat cancers.

Recent notable developments include the activation of the first U.S. site for the Phase 2 expansion trial of THIO-101 in NSCLC in April 2026, and the expectation that a recent $33 million capital raise will fully fund its pivotal Phase 3 trial. In March 2026, MAIA Biotechnology reported encouraging overall survival data, exceeding two years for eight patients in its ongoing Phase 2 NSCLC clinical trial, and closed a $30 million public offering. The company's lead candidate, ateganosine, has received FDA Fast Track designation for NSCLC and FDA Rare Pediatric Disease Designation for pediatric-type diffuse high-grade gliomas. Dr. Vlad Vitoc serves as CEO and Chairman, leading the company's strategic direction in the immuno-oncology market.